JP4708661B2 - 増強された３’転写終結構造を含む、レトロウイルスベクター - Google Patents
増強された３’転写終結構造を含む、レトロウイルスベクター Download PDFInfo
- Publication number
- JP4708661B2 JP4708661B2 JP2001582562A JP2001582562A JP4708661B2 JP 4708661 B2 JP4708661 B2 JP 4708661B2 JP 2001582562 A JP2001582562 A JP 2001582562A JP 2001582562 A JP2001582562 A JP 2001582562A JP 4708661 B2 JP4708661 B2 JP 4708661B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- retroviral vector
- ltr
- heterologous
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013598 vector Substances 0.000 title claims description 209
- 230000001177 retroviral effect Effects 0.000 title claims description 101
- 230000005030 transcription termination Effects 0.000 title description 47
- 230000008488 polyadenylation Effects 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 76
- 238000011144 upstream manufacturing Methods 0.000 claims description 43
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 32
- 108091026890 Coding region Proteins 0.000 claims description 31
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 28
- 239000003623 enhancer Substances 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000002458 infectious effect Effects 0.000 claims description 9
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 241000701489 Cauliflower mosaic virus Species 0.000 claims description 6
- 108010052219 lamin B2 Proteins 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 102100026519 Lamin-B2 Human genes 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001566 pro-viral effect Effects 0.000 claims description 4
- 102000004381 Complement C2 Human genes 0.000 claims description 3
- 108090000955 Complement C2 Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 description 57
- 125000003729 nucleotide group Chemical group 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 39
- 241001430294 unidentified retrovirus Species 0.000 description 37
- 238000004806 packaging method and process Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 20
- 230000010076 replication Effects 0.000 description 16
- 230000010354 integration Effects 0.000 description 15
- 238000003780 insertion Methods 0.000 description 14
- 230000037431 insertion Effects 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000035897 transcription Effects 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000003111 delayed effect Effects 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108091034057 RNA (poly(A)) Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108700005077 Viral Genes Proteins 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 101100421779 Arabidopsis thaliana SNL3 gene Proteins 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241000700735 Ground squirrel hepatitis virus Species 0.000 description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 description 4
- 101100042631 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIN3 gene Proteins 0.000 description 4
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 101000993321 Homo sapiens Complement C2 Proteins 0.000 description 3
- 102100034353 Integrase Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000283925 Spermophilus Species 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 108010078428 env Gene Products Proteins 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000714230 Avian leukemia virus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 101150047047 gag-pol gene Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20388400P | 2000-05-12 | 2000-05-12 | |
| US60/203,884 | 2000-05-12 | ||
| PCT/IB2001/000826 WO2001085974A2 (en) | 2000-05-12 | 2001-05-14 | Retroviral vectors comprising an enhanced 3' transcription termination structure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003532426A JP2003532426A (ja) | 2003-11-05 |
| JP2003532426A5 JP2003532426A5 (enExample) | 2008-07-03 |
| JP4708661B2 true JP4708661B2 (ja) | 2011-06-22 |
Family
ID=22755701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001582562A Expired - Fee Related JP4708661B2 (ja) | 2000-05-12 | 2001-05-14 | 増強された３’転写終結構造を含む、レトロウイルスベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620595B2 (enExample) |
| EP (1) | EP1283895A2 (enExample) |
| JP (1) | JP4708661B2 (enExample) |
| AU (1) | AU2001258668A1 (enExample) |
| CA (1) | CA2408786C (enExample) |
| IL (2) | IL152527A0 (enExample) |
| NZ (1) | NZ522264A (enExample) |
| WO (1) | WO2001085974A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| NZ554035A (en) * | 2004-09-29 | 2009-11-27 | Pioneer Hi Bred Int | Corn event DAS-59122-7 and methods for detection thereof |
| WO2012018607A2 (en) * | 2010-07-26 | 2012-02-09 | Adv Biologics, Inc. | Vectors and methods for recombinant protein expression |
| CN102533863A (zh) * | 2011-11-25 | 2012-07-04 | 上海市儿童医院 | 一种低通读率慢病毒载体及方法 |
| CN102443604B (zh) * | 2011-11-25 | 2014-12-31 | 上海市儿童医院 | 一种安全性慢病毒载体及其应用 |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
-
2001
- 2001-05-14 CA CA2408786A patent/CA2408786C/en not_active Expired - Fee Related
- 2001-05-14 IL IL15252701A patent/IL152527A0/xx unknown
- 2001-05-14 AU AU2001258668A patent/AU2001258668A1/en not_active Abandoned
- 2001-05-14 WO PCT/IB2001/000826 patent/WO2001085974A2/en not_active Ceased
- 2001-05-14 US US09/855,159 patent/US6620595B2/en not_active Expired - Lifetime
- 2001-05-14 EP EP01931987A patent/EP1283895A2/en not_active Withdrawn
- 2001-05-14 JP JP2001582562A patent/JP4708661B2/ja not_active Expired - Fee Related
- 2001-05-14 NZ NZ522264A patent/NZ522264A/en not_active IP Right Cessation
-
2002
- 2002-10-28 IL IL152527A patent/IL152527A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20020042136A1 (en) | 2002-04-11 |
| WO2001085974A2 (en) | 2001-11-15 |
| WO2001085974A3 (en) | 2002-07-04 |
| IL152527A (en) | 2009-06-15 |
| EP1283895A2 (en) | 2003-02-19 |
| NZ522264A (en) | 2004-08-27 |
| US6620595B2 (en) | 2003-09-16 |
| IL152527A0 (en) | 2003-05-29 |
| CA2408786A1 (en) | 2001-11-15 |
| AU2001258668A1 (en) | 2001-11-20 |
| CA2408786C (en) | 2012-05-29 |
| JP2003532426A (ja) | 2003-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naldini et al. | Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. | |
| JP4640742B2 (ja) | 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段 | |
| US7056699B2 (en) | Lentiviral LTR-deleted vector | |
| ES2959326T3 (es) | Líneas celulares estables para producción retroviral | |
| CA2328404C (en) | Novel lentiviral packaging cells | |
| KR20160122125A (ko) | 바이러스 벡터 생산 시스템 | |
| Anson et al. | Rational development of a HIV‐1 gene therapy vector | |
| AU778106B2 (en) | Synthetic gene for expressing active retroviral protein in eukaryotes | |
| JP4708661B2 (ja) | 増強された３’転写終結構造を含む、レトロウイルスベクター | |
| US20060019393A1 (en) | Minimal lentiviral vector system | |
| US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
| Fuller et al. | Helper plasmids for production of HIV-1-derived vectors | |
| Barker et al. | Vectors derived from the human immunodeficiency virus, HIV-1 | |
| JP2003532426A5 (enExample) | ||
| US20230151388A1 (en) | Modified vectors for production of retrovirus | |
| US20060134137A1 (en) | Transduction vector based on modified HIV-2 | |
| Kafri | Gene Delivery by Lentivirus Vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110112 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110210 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110308 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110317 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |